FDA approves BAVENCIO in association with axiathani as a first-line treatment for patients with advanced renal cell carcinoma (RCC)
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the United StatesThe FDA(http://approved BAVENCIO (Avelumab) in conjunction with INLYTA as a first-line treatment for patients with advanced renal cell carcinoma (RCC)this is also the first time the FDA has approved PD-L1 immunotherapy as a combination of treatments for patients with advanced kidney cancerAbout BAVENCIO
BAVENCIO is a PD-L1 inhibitor and is a high-profile class of cancer immunotherapyThe drug has been approved by the FDA for the treatment of metastatic merkel cell carcinoma (MCC) and localized advanced or metastatic urinary disease (mUC) patients who have undergone chemotherapyThe approval of a new combination of BAVENCIO and axioinib provides patients with advanced kidney cancer with much-needed treatment optionsThe approval was based on the results of the phase III ClinicalTrial(http://of JAVELIN Renal 101, which included 886 patients with advanced renal cell carcinoma who had not been treated and did not take into account PD-L1 expressionThe results showed thatcompared to sconeinib, combined therapy reduced the risk of progression or death in patients with advanced kidney cancer by 31%;Patients in the combined therapy group were 2 times more effective than the sconetinib group (51.4% VS25.7%)
;Combination therapy extends the patient's progression-free survival (PFS) by 5.4 months (13.8:8.4 months);In terms of safety, the co-treatment group had a lower percentage of side effects
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
